These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25246753)

  • 1. Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.
    Lee JE; Ryu DH; Jeong HJ; Kim JH; Jun JE; Kim JS; Lee SY
    J Korean Med Sci; 2014 Sep; 29(9):1317-9. PubMed ID: 25246753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Non-Genetic Factors Affecting the Quality of Anticoagulation Control and Vascular Events in Atrial Fibrillation.
    Park YK; Lee MJ; Kim JH; Lee JS; Park RW; Kim GM; Chung CS; Lee KH; Kim JS; Lee SY; Bang OY
    J Stroke Cerebrovasc Dis; 2017 Jun; 26(6):1383-1390. PubMed ID: 28412319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy].
    Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG
    Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
    Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
    Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature.
    Tomisti L; Del Re M; Bartalena L; Tanda ML; Pucci A; Pambianco F; Danesi R; Braverman LE; Martino E; Bogazzi F
    Endocr Pract; 2013; 19(6):1043-9. PubMed ID: 23807523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to use warfarin assays in patient management: analysis of 437 warfarin measurements in a clinical setting.
    Lee K; Woo HI; Bang OY; On YK; Kim JS; Lee SY
    Clin Pharmacokinet; 2015 May; 54(5):517-25. PubMed ID: 25466603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Processes and barriers to implementation of point-of-care genotype-guided dosing of warfarin into UK outpatient anticoagulation clinics.
    Fitzgerald G; Prince C; Downing J; Reynolds J; Zhang JE; Hanson A; Alfirevic A; Pirmohamed M
    Pharmacogenomics; 2019 Jun; 20(8):599-608. PubMed ID: 31046595
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of genetic and patient factors on warfarin pharmacodynamics following warfarin withdrawal: Implications for patients undergoing surgery.
    Abohelaika S; Wynne H; Avery P; Kampouraki E; Kamali F
    Thromb Res; 2018 Nov; 171():167-170. PubMed ID: 30321703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke.
    Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z
    J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of warfarin dose requirements in South African patients attending an anticoagulation clinic.
    Schapkaitz E; Sithole J
    J Vasc Nurs; 2017 Mar; 35(1):27-30. PubMed ID: 28224948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
    Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
    Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interactions between warfarin and lenvatinib in a patient with the CYP2C9*1/*3 and VKORC1-1639G/A genotype.
    Yagishita H; Minami S; Akamine Y; Kato S; Iijima K; Miura M
    J Clin Pharm Ther; 2019 Dec; 44(6):977-980. PubMed ID: 31468576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing quality of anticoagulation control and warfarin dosage in patients after aortic valve replacement within the 3 months of follow up.
    Wypasek E; Mazur P; Bochenek M; Awsiuk M; Grudzien G; Plicner A; Undas A
    J Physiol Pharmacol; 2016 Jun; 67(3):385-93. PubMed ID: 27511999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
    Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
    ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extremely low therapeutic doses of acenocoumarol in a patient with
    Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
    Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
    Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
    Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin.
    Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK
    Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.